Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 321

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 321
---
 nine-month period ended September 30, 2023. NOTE 11 – 401(k) RETIREMENT SAVINGS PLAN The Company sponsors a 401(k) defined contribution plan covering eligible employees who elect to participate. The Company is allowed to make discretionary profit sharing and 401(k) matching contributions as defined in the plan and as approved by the Board of Directors. The Company’s contributions for the period from February 14, 2024 through September 30, 2024, was $ 40,459and Predecessor contributions during the period from January 1, 2024 through February 13, 2024 was $ 8,657. The Company’s contributions for the three-months ended September 30, 2024 was $ 16,700. The Predecessor made nocontributions in the three- or nine-months ended September 30, 2023. NOTE 12 – Subsequent Events On October 1, 2024, the Company’s Board of Directors granted Directors and Officers options to purchase up to 45,230shares of common stock for $ 10.00per share. The grants have various vesting conditions, including time-based and performance-based terms. Additionally, on October 1, 2024, the exercise price of all other outstanding options granted under the 2024 Plan was adjusted to $ 10.00per share, with all other terms of the original grant to remain without adjustment. On October 23, 2024, the trading price for CERo common stock closed under $ 0.10(prior to the Reverse Stock Split) and was the tenth consecutive trading day to do so. On October 24, 2024, the Company received letter from the staff at The Nasdaq Global Market (“Nasdaq”) notifying the Company that, because its Common Stock had a closing bid price of $ 0.10or less for tenconsecutive trading days, it was no longer eligible to rely upon the 180-day cure period that commenced when the Company received notice in July 2024 that the closing bid price was below $ 1.00for tenconsecutive trading days and was scheduled to expire on January 15, 2025. In addition, on October 30, 2024, the Company received a letter from the staff at Nasdaq notifying the Company that it had not regained compliance with the continued listing requirement to maintain a minimum market value of $ 50,000,000for its listed